tiprankstipranks
Advertisement
Advertisement

CORT Stock Latest News

Corcept Therapeutics Signals Big Growth After Key Wins
Company AnnouncementsCorcept Therapeutics Signals Big Growth After Key Wins
3d ago
CORT
Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright
PremiumThe Fly
Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright
3d ago
CORT
Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler
PremiumThe Fly
Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler
6d ago
CORT
Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study
PremiumThe Fly
Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study
7d ago
CORT
Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth
PremiumCompany Announcements
Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth
7d ago
8K
CORT
Corcept Therapeutics reports Q1 EPS (30c), consensus (14c)
PremiumThe FlyCorcept Therapeutics reports Q1 EPS (30c), consensus (14c)
7d ago
CORT
Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M
Premium
The Fly
Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M
7d ago
CORT
Analyst Reiterates Buy on Corcept, Sees Upside with Unchanged $110 Target as Korlym Growth Set to Re-Accelerate and Lifyorli Ramps
Premium
Ratings
Analyst Reiterates Buy on Corcept, Sees Upside with Unchanged $110 Target as Korlym Growth Set to Re-Accelerate and Lifyorli Ramps
9d ago
CORT
Is CORT a Buy, Before Earnings?
PremiumPre-Earnings
Is CORT a Buy, Before Earnings?
9d ago
CORT
Corcept Therapeutics presents final overall survival data from ROSELLA trial
PremiumThe Fly
Corcept Therapeutics presents final overall survival data from ROSELLA trial
27d ago
CORT
Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims
PremiumMarket News
Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims
1M ago
CORT
Corcept Therapeutics presents data from Momentum trial at ACC 2026
PremiumThe Fly
Corcept Therapeutics presents data from Momentum trial at ACC 2026
1M ago
CORT
Corcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research
PremiumThe FlyCorcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research
1M ago
CORT
Corcept Therapeutics price target raised to $110 from $100 at Canaccord
Premium
The Fly
Corcept Therapeutics price target raised to $110 from $100 at Canaccord
1M ago
CORT
Corcept Faces Investor Suit Over Relacorilant NDA Disclosure 
Premium
Class Action
Corcept Faces Investor Suit Over Relacorilant NDA Disclosure 
1M ago
CORT
Corcept Therapeutics price target raised to $110 from $100 at Canaccord
PremiumThe Fly
Corcept Therapeutics price target raised to $110 from $100 at Canaccord
1M ago
CORT
PremiumCompany Announcements
Corcept Wins FDA Approval for Lifyorli Ovarian Cancer Therapy
1M ago
8K
CORT
Corcept confirms FDA approves Lifyorli for platinum-resistant ovarian cancer
PremiumThe Fly
Corcept confirms FDA approves Lifyorli for platinum-resistant ovarian cancer
1M ago
CORT
Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?
PremiumMarket News
Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?
1M ago
CORT
TEVA
PremiumRatingsCorcept Therapeutics: Early Lifyorli Approval and Robust Long‑Term Sales Outlook Underpin Buy Rating and $60 Target
1M ago
CORT
Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright
Premium
The Fly
Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright
1M ago
CORT
Corcept Therapeutics rises 28.6%
Premium
The Fly
Corcept Therapeutics rises 28.6%
1M ago
CORT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >